TABLE 2.
Inflammation-related Diseases | Mechanism of action | Trends in action | Refs |
---|---|---|---|
Pulmonary fibrosis | NF-κB/NLRP3-mediated epithelial–mesenchymal transition and inflammation (−) | p-p65/p65, IκBα, NLRP3, CASP1, ASC, IL-1β, IL-18, GSDMDN, FN, VIM, CDH2, MMP-2, MMP-9↓ | Peng et al. (2020) |
Osteoarthritis (OA) | Reverse collagen II and aggrecan degradation; Nrf2 and NF-κB signaling pathways (−) | MMP-13, ADAMTS-5, COX-2, iNOS, IL-6, TNF-α, PGE2↓ | Luo et al. (2020) |
MAPK and Wnt/β-catenin signaling pathways (−) | MMP1, MMP13, ADAMTS-5, Wnt3a↓; COL2A1, ACAN↑ | Liu et al. (2020b) | |
TLR4/NF-κB pathways (−) | IL-1β, TNF-α, IL-6, SOD, MDA, ICAM-1, MCP-1, CASP3, Bax/Bcl-2, TLR4↓ | Zhang et al. (2017) | |
NF-κB and PI3K/AKT signaling pathways (−) | IL-1β, iNOS, MMP13, ADAMTS-5, COX-2, IL-6↓ | Wang et al. (2019) | |
NF-κB/MAPK signaling pathways (−) | MMP3, MMP9, MMP13, ADAMTS4, ADAMTS5↓ | Yang et al. (2022) | |
PI3K/AKT/mTOR signaling pathways (−) | COL2A1, SOX9, IL-6 APOA1, ABCA1↑; MMP13, CH25H, CYP7B1, AKT, p-AKT, mTOR, p-mTOR↓ | Ju et al. (2021) | |
Colitis | pro-inflammatory cytokines (−); apoptosis and oxidative stress (−) | MDA, NO, IL-6, TNF-α, Bax↓; SOD, TAS, Bcl-2↑ | Aksit et al. (2023) |
Colitis-associated colorectal cancer | Hedgehog signaling pathway (−) | proliferation, migration, colony formation↓ | Zeng et al. (2022) |
Rheumatoid arthritis (RA) | Regulate the Keap1/Nrf2/HO-1 pathways | IgG, IgE, TNF-α, IL-1β, IL-6, Th1/Th2, HO-1↓; Keap1, Nrf2↑ | Li et al. (2023a) |
Cerebral ischemia/reperfusion damage | Regulate MAPK signaling Pathway | TNF-α, IL-1β, p-JNK, p-p38, iNOS↓; p-ERK1/2↑ | Chen et al. (2020a) |
PI3K/Akt pathway (+) | Nrf2, HO-1, SOD↑; ROS, NF-κB↓ | Xie et al. (2023) | |
Inflammatory responses and oxidative stress (−); MAPK/NF-κB pathways (−) | MDA, SOD, GSH, IL-6, IL-1β, NO, p65, p38↓ | Zhang et al. (2022) | |
Renal ischemia–reperfusion injury | MAPK pathway (−); Pro-inflammatory macrophage polarization (−) | ERK, p38, JNK↓ | Deng et al. (2024) |
Myocardial ischemia–reperfusion injury | NLRP3 inflammasome activation (−); Akt/mTORC1/NLRP3 signaling pathways (−) | LDH, CK-MB, Myo, ALT, IL-1β, IL-18, cas1, IL-1β, NLRP3, TNF-α↓ | Xu et al. (2020) |
Cognitive deficits | Alleviate LPS-induced cognitive disturbances | AChE, TNF-α, IL-6, Nrf2, LC3 II, mTOR, P62↓ | Baluchnejadmojarad et al. (2018) |
Neuroinflammation-astrocyte | TLR4/NF-κB pathways (−) | TNF-α, IL-1β, IL-6, iNOS↓; IL-4, BDNF↑ | Lu et al. (2021) |
Neuroinflammation-Macrophages | NLRP3 Inflammasome Activation in Macrophages (−) | CASP1, IL-1β↓ | Liu et al. (2017b) |
Neuroinflammation-microglia | Mitigate microglia inflammation; mir-7036a-5p/MAPT/PRKCG/ERK signaling pathways (−) | Mir-7036a-5p, TNF-α, IL-1β, iNOS↓ | Duan et al. (2024) |
Neuroinflammation and microglia activation (−) | NLRP3, CASP1, IL-1β↓ | Bian et al. (2020) | |
Neuroinflammation (−); AKT/NF-κB and p38/JNK pathways (−) | TNF-α, NO, IL-6, IL-1β, iNOS↓ | You et al. (2018) | |
Neuroinflammation-microglia, astrocyte | Microglia inflammatory activation (−) | NO, TNF-α, IL-1, ROS, iNOS, NF-κB, JNK, ERK↓ | Wang et al. (2011) |
Kidney injury | Inflammation and oxidative stress (−); regulate Nrf2/PPAR-c/PGC-1a/NF-κB/TLR4 pathways | BUN, ROS, MDA, IL-10, TLR4, NF-κB, TNF-α↓; Nrf2, HO-1↑ | Shahmohammadi et al. (2023) |
NLRP3 inflammasome activation (−) | BUN, SCr, Kim-1, IL-18, NGAL, Cys-C↓ | Li et al. (2020) | |
Asthma | Smad/MAPK pathways (−) | CDH1↑, CDH2, α-SMA↓ | Li et al. (2024a) |
Foam cell | Autophagy (+); NLRP3 inflammasome activation (−) | Plin2, LC3B-II, Map1lc3b, Becn1↑ | Gao et al. (2024) |
Intervertebral disc degeneration | Regulate Rab8a via the PI3K/PTEN/Akt pathway | p62↓, Beclin-1, Rab8a, ATG5↑ | Hu et al. (2022) |
NLRP3 inflammasome activation (−); NF-κB/MAPK signaling pathways (−) | p-p38, p-JNK↓; p-ERK1/2↑ | Wang et al. (2022b) |
Annotation “+”: activate; “-”: suppress; “↑”: increase/upregulated; “↓”: reduce/downregulate.